Editas Medicine, Inc. Scheduled to Announce Q3 2026 Financial Results
Editas Medicine, Inc. is scheduled to report its third-quarter 2026 financial results on November 9, 2026.
Stocks · News reference
Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target
Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6
Editas Medicine Receives Approval To Initiate Its Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In Australia
The trial has received Human Research Ethics Committee (HREC) approval and completed the Clinical Trial Notification (CTN) process with Australia’s Therapeutic Goods Administration (TGA) and has also been submitted for
8-K filing — Editas Medicine, Inc. (EDIT)
Filed: 2026-10-08 AccNo: 0001650664-26-000093 Size: 292 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.
This Editas Medicine Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Analysts upgraded Microsoft, Graphic Packaging, Editas Medicine and Lakefront Biotherapeutics, with mixed price-target changes.